Review
Medicine, Research & Experimental
Kyung-Han Lee, Kyung-Ho Jung, Jin Hee Lee
Summary: Monoclonal antibodies have revolutionized lymphoma management and the development of new antibody therapeutics and radioimmunotherapy can further enhance treatment efficacy. Immuno-PET with radiolabeled antibodies can facilitate the development of new treatments and provide valuable information for patient selection and treatment response assessment, showing great potential in lymphoma management.
MOLECULAR PHARMACEUTICS
(2022)
Article
Biochemical Research Methods
Dave Lumen, Danielle Vugts, Marion Chomet, Surachet Imlimthan, Mirkka Sarparanta, Ricardo Vos, Maxime Schreurs, Mariska Verlaan, Pauline A. Lang, Eero Hippelainen, Wissam Beaino, Albert D. Windhorst, Anu J. Airaksinen
Summary: Recent advances in engineered antibodies have enabled the development of tailored, target-specific antibodies. This study compared the pretargeted and targeted approaches using a new Zr-89-labeled tetrazine as a bio-orthogonal ligand. The results showed that the pretargeted approach had lower tumor uptake but comparable tumor-to-non-target tissue ratios and lower absorbed doses.
BIOCONJUGATE CHEMISTRY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Y. Touchefeu, C. Bailly, E. Frampas, T. Eugene, C. Rousseau, M. Bourgeois, C. Bossard, A. Faivre-Chauvet, A. Rauscher, D. Masson, A. David, E. Cerato, T. Carlier, R. M. Sharkey, D. M. Goldenberg, J. Barbet, F. Kraeber-Bodere, C. Bodet-Milin
Summary: This pilot study evaluated the imaging performance of pretargeted immuno-PET using anti-CEA monoclonal antibody TF2 and [Ga-68]Ga-labelled IMP288 in patients with metastatic CRC. The results showed a positive reaction in 9/11 patients, with an impact on management for 2 patients.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Medicine, General & Internal
Alexandre Lugat, Clement Bailly, Michel Cherel, Caroline Rousseau, Francoise Kraeber-Bodere, Caroline Bodet-Milin, Mickael Bourgeois
Summary: Radioimmunoconjugates have been widely used in nuclear medicine applications for over 30 years. Recent advances in cancer biology have led to the discovery of new molecular targets specific to certain patient subgroups, allowing for the development of specifically tailored therapeutic approaches. Immuno-positron emission tomography (immuno-PET) is a non-invasive imaging modality that utilizes monoclonal antibodies for in vivo characterization of tumor biomarkers, providing valuable information on tumor targeting. Immuno-PET shows great potential in various nuclear medicine applications, including staging/stratification, theranostic approaches, and predictive/prognostic biomarkers. Finding the right balance between isotope choice and immunologic structure is crucial for the development of radiopharmaceutical drugs for immuno-PET.
FRONTIERS IN MEDICINE
(2022)
Article
Chemistry, Multidisciplinary
Jing Wang, Liangang Zhuo, Peng Zhao, Wei Liao, Hongyuan Wei, Yuchuan Yang, Shuming Peng, Xia Yang
Summary: This study reveals that the Lu-177 labeled CA19-9 mAb has a therapeutic effect on CRC with limited side effects. Additionally, the Zr-89 labeled mAb can be used for the diagnosis of CRC.
CHINESE CHEMICAL LETTERS
(2022)
Article
Oncology
Jamie M. Sperger, Kyle T. Helzer, Charlotte N. Stahlfeld, Dawei Jiang, Anupama Singh, Katherine R. Kaufmann, David J. Niles, Erika Heninger, Nicholas R. Rydzewski, Liguo Wang, Liewei Wang, Rendong Yang, Yanan Ren, Jonathan W. Engle, Peng Huang, Christos E. Kyriakopoulos, Susan F. Slovin, Howard R. Soule, Shuang G. Zhao, Manish Kohli, Scott T. Tagawa, Weibo Cai, Scott M. Dehm, Joshua M. Lang
Summary: This study analyzed the expression of biomarkers in prostate cancer patients and demonstrated that TROP-2 can serve as a cell surface target for isolating circulating tumor cells, and it may serve as a predictive biomarker for antibody-drug conjugates.
CLINICAL CANCER RESEARCH
(2023)
Article
Biochemical Research Methods
Samantha M. Sarrett, Outi Keinanen, Eric J. Dayts, Guillaume Dewaele-Le Roi, Cindy Rodriguez, Kathryn E. Carnazza, Brian M. Zeglis
Summary: This approach utilizes the rapid, bio-orthogonal inverse electron demand Diels-Alder reaction between a radiolabeled tetrazine and a trans-cyclooctene-bearing antibody for pretargeted positron emission tomography imaging and endoradiotherapy. By labeling the antibody after it has reached its target, this method reduces radiation doses to healthy tissues while achieving high activity concentrations in target tissues. Proper training in radiation safety and the handling of laboratory mice is crucial for the successful implementation of this protocol.
Article
Radiology, Nuclear Medicine & Medical Imaging
Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, Frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, Delphine Drui, David M. Goldenberg, Robert M. Sharkey, Jacques Barbet, Francoise Kraeber-Bodere
Summary: The study optimized pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the 68 Ga-labeled IMP288 peptide for immuno-PET in medullary thyroid carcinoma (MTC) patients. The immuno-PET showed a higher overall sensitivity than F-18-DOPA PET/CT for detecting metastases, except for lung metastases where CT remained the most effective examination.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Multidisciplinary Sciences
Sung Chang Lee, Jennifer S. Y. Ma, Min Soo Kim, Eduardo Laborda, Sei-Hyun Choi, Eric N. Hampton, Hwayoung Yun, Vanessa Nunez, Michelle T. Muldong, Christina N. Wu, Wenxue Ma, Anna A. Kulidjian, Christopher J. Kane, Vadim Klyushnichenko, Ashley K. Woods, Sean B. Joseph, Mike Petrassi, John Wisler, Jing Li, Christina A. M. Jamieson, Peter G. Schultz, Chan Hyuk Kim, Travis S. Young
Summary: The study introduced a unique semisynthetic bispecific antibody, CCW702, which showed specific and potent in vitro cytotoxicity, good tolerability and subcutaneous bioavailability in mice and cynomolgus monkeys, supporting a weekly dosing regimen testing in patients.
Article
Multidisciplinary Sciences
Alex A. Shepherd, Bigitha D. Bennychen, Anne Marcil, Darin Bloemberg, Robert Pon, Risini A. Weeratna, Scott A. McComb
Summary: Bi-specific T-cell engager antibodies (BiTEs) are synthetic fusion molecules that induce active contact between T-cells and antigen expressing cells. The current process for BiTE development is time-consuming and costly. This study aims to establish a cost-efficient method for generating and evaluating novel BiTE sequences without purification.
Article
Radiology, Nuclear Medicine & Medical Imaging
Weiyu Chen, Miao Li, Muhsin H. Younis, Todd E. Barnhart, Dawei Jiang, Tuanwei Sun, Joshua M. Lang, Jonathan W. Engle, Min Zhou, Weibo Cai
Summary: The study demonstrated that Trop-2 can effectively be used as a target for pancreatic cancer imaging, with Zr-89-DFO-AF650 showing high specificity to Trop-2 and strong targeting efficacy in animal models.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jessica E. Wijngaarden, Marc C. Huisman, Yvonne W. S. Jauw, Guus A. M. S. van Dongen, Henri N. J. M. Greuter, Robert C. Schuit, Matthew Cleveland, Elske C. Gootjes, Danielle J. Vugts, C. Willemien Menke-van der Houven van Oordt, Ronald Boellaard
Summary: This study assesses the validity of three commonly used quantification parameters (SUV, TPR, and TBR) in quantifying reversible Zr-89-Immuno-PET uptake. The results showed that SUV, TPR, and TBR are valid quantification parameters for constant mass doses. However, for variable mass doses, only TPR and TBR provide reliable quantification values, while SUV does not consider patient and mass dose-specific plasma clearance.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Biochemical Research Methods
Vilma I. J. Jallinoja, Brandon D. Carney, Meiying Zhu, Kavita Bhatt, Paul J. Yazaki, Jacob L. Houghton
Summary: This study investigates the utilization of antibody-based host-guest chemistry for pretargeted positron emission tomography, aiming to overcome challenges related to in vivo stability and modularity of current pretargeting platforms. The results demonstrate that the novel pretargeting approach utilizing a cucurbit[7]uril host molecule modified antibody and a Ga-68-radiolabeled ferrocene guest radioligand leads to significantly higher tumor uptake compared to nonpretargeted approaches.
BIOCONJUGATE CHEMISTRY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Guus A. M. S. van Dongen, Wissam Beaino, Albert D. Windhorst, Gerben J. C. Zwezerijnen, Daniela E. Oprea-Lager, N. Harry Hendrikse, Cornelis van Kuijk, Ronald Boellaard, Marc C. Huisman, Danielle J. Vugts
Summary: The identification of molecular drivers of disease and the rise of biotherapeutics have impacted clinical care, but also presented challenges. The application of Zr-89-immuno-PET in drug development shows promise in guiding the design, development, and application of biologic drugs, with increasing potential for understanding drug-target combinations in clinical studies.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Oncology
Jonatan Dewulf, Christel Vangestel, Yannick Verhoeven, Jorrit De Waele, Karen Zwaenepoel, Peter A. van Dam, Filipe Elvas, Tim van den Wyngaert
Summary: RANKL has been recognized as an important target in the tumor microenvironment for promoting an immunosuppressive environment and resistance to immunotherapy. Assessment of RANKL expression is challenging due to its heterogeneous nature, but the development of anti-RANKL immuno-PET tracers shows promise in non-invasively monitoring RANKL expression.
Article
Radiology, Nuclear Medicine & Medical Imaging
Stefano Fanti, Karolien Goffin, Boris A. Hadaschik, Ken Herrmann, Tobias Maurer, Steven MacLennan, Daniela E. Oprea-Lager, Wim J. G. Oyen, Olivier Rouviere, Nicolas Mottet, Anders Bjartell
Summary: PSMA PET/CT can be used to evaluate treatment response in patients with metastatic prostate cancer before and after any local and systemic treatment. Ideally, imaging criteria should categorize patients as responders, patients with stable disease, partial response, and complete response, or as non-responders. Specific clinical scenarios deserve special consideration.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elizabeth J. de Koster, Wyanne A. Noortman, Jacob M. Mostert, Jan Booij, Catherine B. Brouwer, Bart de Keizer, John M. H. de Klerk, Wim J. G. Oyen, Floris H. P. van Velden, Lioe-Fee De Geus-Oei, Dennis Vriens
Summary: The study aimed to evaluate whether quantitative [F-18]FDG-PET/CT assessment and radiomic analysis of [F-18]FDG-positive thyroid nodules could improve the preoperative differentiation of indeterminate thyroid nodules. The results showed that applying distinct SUV cut-offs for non-Hurthle cell and Hurthle cell nodules can optimize the ability to rule out malignancy, while radiomic analysis did not provide additional differentiation for [F-18]FDG-positive nodules.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elizabeth J. de Koster, Lioe-Fee de Geus-Oei, Adrienne H. Brouwers, Eveline W. C. M. van Dam, Lioe-Ting Dijkhorst-Oei, Adriana C. H. van Engen-van Grunsven, Wilbert B. van den Hout, Tamira K. Klooker, Romana T. Netea-Maier, Marieke Snel, Wim J. G. Oyen, Dennis Vriens
Summary: The study aimed to assess the impact of an [F-18]FDG-PET/CT-driven diagnostic workup on patients with indeterminate thyroid nodules. The results showed that this workup accurately reduced futile surgeries by 40% and should be limited to non-Hurthle cell nodules.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Rheumatology
Chantal A. M. Bouman, Noortje van Herwaarden, Annelies B. Blanken, Conny J. Van der Laken, Martin Gotthardt, Wim J. G. Oyen, Alfons A. den Broeder, Aatke van der Maas, Cornelia H. van den Ende
Summary: FDG-PET arthritis scoring in RA patients with low disease activity is reliable and has some construct validity, but no predictive values were found for FDG-PET parameters for successful tapering and/or discontinuation of TNFi.
Article
Radiology, Nuclear Medicine & Medical Imaging
Elizabeth J. de Koster, Dennis Vriens, Maarten O. van Aken, Lioe-Ting Dijkhorst-Oei, Wim J. G. Oyen, Robin P. Peeters, Abbey Schepers, Lioe-Fee De Geus-Oei, Wilbert B. van den Hout
Summary: This study evaluates the cost-effectiveness of an [F-18]FDG-PET/CT-driven diagnostic workup compared to diagnostic surgery for thyroid nodules with Bethesda III/IV cytology. The results show that [F-18]FDG-PET/CT avoids unnecessary diagnostic surgeries and reduces costs while maintaining quality of life.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Fijs W. B. van Leeuwen, Margret Schottelius, Felix M. Mottaghy, Fabien Hyafil, Mark Lubberink, Gabriela Kramer-Marek, Wim J. G. Oyen
Article
Oncology
Maarten J. van der Doelen, Irma M. Oving, Dirk N. J. Wyndaele, Jean-Paul van Basten, Frederiek Terheggen, Addy C. M. van de Luijtgaarden, Wim J. G. Oyen, W. Dick van Schelven, Franchette van den Berkmortel, Niven Mehra, Marcel J. R. Janssen, Judith B. Prins, Winald R. Gerritsen, Jose A. E. Custers, Inge M. van Oort
Summary: This study evaluated the health-related quality of life, psychological distress, and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223. The study found that patients who discontinued radium-223 therapy had worse HR-QoL, psychological distress, and fatigue at baseline and more frequent deterioration over time compared to patients who completed therapy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Endocrinology & Metabolism
Elizabeth J. de Koster, Olga Husson, Eveline W. C. M. van Dam, G. Sophie Mijnhout, Romana T. Netea-Maier, Wim J. G. Oyen, Marieke Snel, Lioe-Fee de Geus-Oei, Dennis Vriens
Summary: The study examined HRQoL in patients undergoing FDG-PET/CT for an indeterminate thyroid nodule, finding that active surveillance following a negative FDG result resulted in stable HRQoL scores over a year. Patients with benign histopathology who underwent diagnostic surgery had more cognitive impairment and physical problems, but improved goitre symptoms and anxiety. Anxiety also decreased in patients with malignant histopathology.
ENDOCRINE CONNECTIONS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Elizabeth J. de Koster, Adriana C. H. van Engen-van Grunsven, Johan Bussink, Cathelijne Frielink, Lioe-Fee de Geus-Oei, Benno Kusters, Hans Peters, Wim J. G. Oyen, Dennis Vriens
Summary: This study explored the association between [F-18]FDG uptake and the quantitative expression of immunohistochemical markers related to glucose metabolism, hypoxia, and cell proliferation in benign and malignant thyroid nodules of indeterminate cytology. The results showed that the expression of GLUT1, HK2, and MCT4 increased in [F-18]FDG-positive benign nodules and thyroid carcinomas as compared to [F-18]FDG-negative benign nodules, and VEGF expression was higher in thyroid carcinomas.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Letter
Radiology, Nuclear Medicine & Medical Imaging
Dennis Vriens, Elizabeth J. de Koster, Lioe-Fee de Geus-Oei, Wim J. G. Oyen, EfFECTS trial consortium
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Medicine, General & Internal
Lidija Antunovic, Alessia Artesani, Michael Coniglio, Wim J. G. Oyen, Michele Ciccarelli, Carlo Selmi, Arturo Chiti, Martina Sollini
Summary: This study evaluated the diagnostic accuracy of [F-18]-fluorodeoxyglucose ([F-18]FDG) PET/CT in large vessel vasculitis (LVV) and found that an experienced reader had higher accuracy compared to a less experienced one. The expert reader performed better in patients with normal BMI, normal glycemia, younger age, and no ongoing therapy. The use of semi-quantitative parameters did not improve the diagnostic performance of the readers.
Article
Radiology, Nuclear Medicine & Medical Imaging
H. Adams, E. M. W. van de Garde, D. J. Vugts, J. C. Grutters, Wim. J. G. Oyen, R. G. Keijsers
Summary: This study investigates the use of imaging CD20-positive cells in predicting the response to anti-CD20 treatment for immune-mediated interstitial lung disease. PET/CT imaging was performed on 21 patients, and it was found that the uptake of [89Zr]-rituximab in the lungs correlated with changes in pulmonary function test results and treatment outcomes. Patients with a higher uptake of [89Zr]-rituximab had better response to treatment. Therefore, [89Zr]-rituximab PET imaging may serve as a potential predictive biomarker for anti-CD20 therapy.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Oncology
Elizabeth J. de Koster, Willem E. Corver, Lioe-Fee de Geus-Oei, Wim J. G. Oyen, Dina Ruano, Abbey Schepers, Marieke Snel, Tom van Wezel, Dennis Vriens, Hans Morreau
Summary: This study described the patterns of copy number alterations (CNA) in benign and malignant oncocytic cell thyroid neoplasms (OCN) using a next-generation sequencing (NGS) panel. The study found that the CNA patterns differed between benign and malignant cases, and suggested the application of CNA-LOH analysis using the NGS panel in the molecular diagnostics of OCN.
ENDOCRINE-RELATED CANCER
(2023)
Article
Oncology
Stefano Fanti, Alberto Briganti, Louise Emmett, Karim Fizazi, Silke Gillessen, Karolien Goffin, Boris A. Hadaschik, Ken Herrmann, Jolanta Kunikowska, Tobias Maurer, Steven MacLennan, Nicolas Mottet, Declan G. Murphy, Daniela E. Oprea-Lager, Joe M. O'Sullivan, Wim J. G. Oyen, Olivier Rouviere, Oliver Sartor, Arnulf Stenzl, Hendrik Van Poppel, Jochen Walz, Wim Witjes, Anders Bjartell
Summary: The use and potential of PSMA PET/CT in prostate cancer treatment and management were assessed and achieved consensus among a panel of experts, particularly in utilizing PSMA PET/CT for patient selection and guiding [177Lu]Lu-PSMA therapy.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Review
Oncology
Miriam N. Mikhail Lette, Diana Paez, Lawrence N. Shulman, Mathias Guckenberger, Jean-Yves Douillard, Wim J. G. Oyen, Francesco Giammarile, Venkatesh Rangarajan, Michelle Ginsberg, Olivier Pellet, Zhongxing Liao, May Abdel Wahab
Summary: This paper emphasizes the importance of improving medical imaging and nuclear medicine infrastructure globally to achieve better outcomes for lung cancer patients. It highlights the significant role of imaging findings in treatment selection and patient outcomes, and discusses the current gaps in diagnostics and therapies. The paper also emphasizes the high burden of lung cancer in low- and middle-income countries and the need for strategic planning to improve population-based outcomes.
JCO GLOBAL ONCOLOGY
(2022)
